UNSPSC 51361934: Hexobarbital sodium

This classification denotes a barbiturate with the molecular formula C12H15N2O3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I788X867K7, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(1-cyclohexen-1-yl)-1,5-dimethyl-, monosodium salt but more generally known as hexobarbital sodium, which bears US NIH Compound Identifier 3608. European Medicines Agency schedules Hexobarbital sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02514MIG.

Most nations, for tariff and trade purposes, schedule hexobarbital sodium under HS 29335400. As of Q4 2014, HEXOBARBITAL SODIUM remains US FDA's Preferred Term for this commodity. Hexobarbital sodium bears US NLM identifiers UMLS ID C0037514 and NCI Concept Code C72808. SMILES: CC1(C(=O)[N-]C(=O)N(C1=O)C)C2=CCCCC2.[NA+].

UNSPSC 51361934 Hexobarbital sodium is a Commodity code that nominally designates a specific barbiturate pharmaceutical, but recent state and local procurement activity shows little alignment with this specific active ingredient. The three most recent opportunities posted under this code—a naloxone and drug deactivation systems bid from Seminole County, Florida; a therapeutic pharmacy initiative direct-to-manufacturer RFI from the Texas Health and Human Services Commission; and a multistate generic pharmaceuticals and OTC products RFP from the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP)—reflect broader pharmaceutical procurement rather than hexobarbital sodium specifically. State and local issuers soliciting under this code include county health departments, state HHS agencies, and multistate cooperative purchasing alliances. The mismatch between the code's nominal scope and the actual work being bought suggests either miscoding on the issuer side or that the code functions as a catch-all for pharmaceutical procurement that does not fit narrower commodity classifications.

Recent activity spans Florida, Texas, and Minnesota, with the MMCAP opportunity serving participating jurisdictions across multiple states including Oregon. The Seminole County IFB (IFB60459723LAS), posted June 30, 2026 with a response deadline of July 26, 2023, seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with vendors responsible for shipping costs and subject to E-Verify compliance, drug-free workplace certification, and potential FEMA-related regulatory requirements. The Minnesota MMCAP RFP (S1070000015802), posted January 20, 2026 with responses due March 26, 2026, establishes multistate contracts for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers, with pricing weighted at 75 percent of evaluation and award effective July 1, 2026. The Texas HHS RFI (HHS0017013), posted April 3, 2026, gathers market intelligence on direct-to-manufacturer prescription programs but carries no committed award value or binding timeline. Given the code's poor fit with actual solicitations, firms pursuing pharmaceutical procurement should verify the correct UNSPSC classification before responding.